These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22267213)

  • 1. In brief: aliskiren trial terminated.
    Med Lett Drugs Ther; 2012 Jan; 54(1382):5. PubMed ID: 22267213
    [No Abstract]   [Full Text] [Related]  

  • 2. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consumer group asks FDA to warn patients about hypertension combination therapy.
    Mitka M
    JAMA; 2012 Nov; 308(20):2070-1. PubMed ID: 23188005
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct renin inhibitor induced renal failure.
    Vallakati A; Chandra PA; Hollander G; Shani J
    Am J Ther; 2014; 21(2):e53-5. PubMed ID: 23665882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension.
    Riccioni G; Vitulano N; D'Orazio N; Bellocci F
    Adv Ther; 2009 Jul; 26(7):700-10. PubMed ID: 19649581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renal effects of combined anti-hypertensive treatments].
    Gallieni M; Olivi L; Mezzina N; Cozzolino M; Cusi D
    Recenti Prog Med; 2010 Feb; 101(2):70-7. PubMed ID: 20433005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren for hypertension: just another option or something truly unique?
    Lee S
    S D Med; 2007 Oct; 60(10):405-6. PubMed ID: 18019776
    [No Abstract]   [Full Text] [Related]  

  • 9. Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials.
    Gao D; Ning N; Niu X; Wei J; Sun P; Hao G
    Am J Hypertens; 2011 May; 24(5):613-21. PubMed ID: 21293386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point.
    Messerli FH; Bangalore S
    Am J Med; 2013 Mar; 126(3):e1-3. PubMed ID: 23332648
    [No Abstract]   [Full Text] [Related]  

  • 11. An evaluation of the latest evidence relating to renin-angiotensin system inhibitors.
    Escobar C; Barrios V
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):847-58. PubMed ID: 23560616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
    N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.
    Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
    J Renin Angiotensin Aldosterone Syst; 2011 Jun; 12(2):102-12. PubMed ID: 21059822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.
    Schlienger RG; Korn JR; Wehler E; Lopez Leon S; Yeaw J
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):465-474. PubMed ID: 28779444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported.
    Rosich Martí I; Allepuz A; Rodriguez Palomar G; Ortin Font F; Soler Cera M
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):91-96. PubMed ID: 27859873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren/hydrochlorothiazide (Tekturna HCT) for hypertension.
    Med Lett Drugs Ther; 2008 Aug; 50(1293):65-6. PubMed ID: 18719523
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.
    Makani H; Bangalore S; Romero J; Wever-Pinzon O; Messerli FH
    Am J Med; 2011 Feb; 124(2):128-35. PubMed ID: 21295192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS blockade, hyperkalemia and AKI--look and you will find.
    Toto RD
    Nat Rev Nephrol; 2012 May; 8(5):257-8. PubMed ID: 22473512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.